[Angiotensin receptor vaccines].

Abstract

Recent clinical studies have shown that RAS inhibitors are effective not only for the prevention of end-organ damage in hypertensive patients, but also for prevention of new-onset hypertension, diabetes mellitus, and atrial fibrillation. Vaccines against the RAS have been developed since the 1950s, and a recent phase IIa placebo-controlled study has confirmed that an angiotensin vaccine causes a significant decrease in blood pressure in hypertensive patients. The results of animal experiments from our and other laboratories have suggested that vaccination against the angiotensin type 1 (AT1) receptor causes a significant decrease in blood pressure in animal models of hypertension, and also ameliorates hypertensive end-organ damage. The angiotensin receptor may therefore be an important target for the development of vaccines for the prevention of hypertension and related complications.

• Authors: Hiroyuki Sasamura, Tatsuhiko Azegami, Hiroshi Itoh
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 69 Issue 9 Pg. 1633-8 (Sep 2011) ISSN: 0047-1852 [Print] Japan
• PMID: 21922766 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Receptors, Angiotensin

Topics

• Humans
• Hypertension (therapy)
• Receptors, Angiotensin (immunology)